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Abstract 
AIM: This longitudinal study aims to evaluate the efficacy of oral itraconazole in the treatment of seborrheic 
dermatitis in Vietnamese patients.  
METHODS: Thirty patients were enrolled at National Hospital of Dermatology and Venereology, Hanoi, Vietnam 
and were treated with oral itraconazole (200 mg daily in 14 days followed by 200 mg weekly in 4 weeks). The 
clinical severity was assessed by a four-parameter scoring system. All patients completed the six-week regimen 
with good adherence.  
RESULTS: At the week 2nd, 70% of the patients had moderate to severe diseases. At the week 6th, 63.4% of the 
patients achieve clearance of the lesions, and none had severe disease. No side effects were reported.  
CONCLUSION: Oral itraconazole can be an option for seborrheic dermatitis because of good efficacy, safety 
profile and adherence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Seborrheic dermatitis (SD) is a chronic skin 
condition characterised by erythema and greasy 
scales in oily areas. It is considered multifactorial, but 
Malassezia furfur has been proved to play a role in the 
pathogenesis [1]. SD is not curable and tends to 
persist and relapse. Skin lesions, especially in the 
face, can affect a patient’s quality of life at different 
degrees. Treatment of SD includes topical corticoid, 
topical or systemic antimycotic, vitamin A acid, and 
other agents [2]. The antifungal regimens have shown 
efficacy in the management of SD, reducing 
Malassezia proliferation and inflammation. Some 
studies have reported the benefit of topical 
ketoconazole or topical corticoid [3], but the evidence 
of oral itraconazole is weak. Therefore, we conducted 
this study to evaluate the efficacy of oral itraconazole 
in Vietnamese SD patients. 
 
 
Methods 
 
We conducted a longitudinal study at the 
National Hospital of Dermatology and Venereology on 
30 seborrheic dermatitis patients who was 18-60 
years old and treated with oral itraconazole (Table 1).  
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Table 1: Patient characteristics 
Age (year), mean ± SD 36.90 ± 10.73 
Male-to-female ratio 1.5 
Age of onset (year), mean ± SD 34.13 ± 12.42 
 
We excluded pregnant or lactating women 
and patients with hepatic, renal or cardiovascular 
diseases, hyperlipidemia, acute infection, malignant 
diseases, HIV, or ≥ 5 Demodex in one slide. 
The standard oral itraconazole regimen was 
200 mg/day in 14 days followed by a single weekly 
dose of 200 mg in 4 weeks. Patients were asked to 
return for follow-up after two, four, and six weeks. In 
all follow-up visits, the severity of SD was assessed 
by a scoring system including four parameters: 
pruritus, burning, erythema, and scaling-each of which 
is given a score from 0 to 3, corresponding to the 
absence or a mild, moderate, or severe presentation 
[4]. A total score of 0, 1-2, 3-4, and ≥ 5 was 
considered cure, or good, moderate, or severe 
disease. We also recorded side effects of oral 
itraconazole, including rash, nausea, vomiting, 
constipation, headache, and dizziness. 
 
 
Results 
 
All patients completed six-week follow-up and 
reported to adhere to the regimen. Changes in the 
severity at each follow-up visits were shown in Figure 
1.  
 
Figure 1: Changes of severity after treatment 
 
After two weeks, 70% of the patients still had 
moderate to severe disease, and only 6.7% had a 
clearance of lesions. However, the proportion of 
patients with clearance of lesions consistently 
increased after four and six weeks. After completing 
the regimen, 63.4% of the patients achieved 
clearance and none had severe disease. 
During 6 weeks of treatment, no side effect 
was observed in all patients.  
 
Figure 2: A) Clinical presentation at baseline; B) Clinical 
presentation after 6 weeks of treatment 
 
 
Discussions 
 
In this study, we evaluated the patient’s 
response to oral itraconazole in the treatment of 
seborrheic dermatitis. After four weeks, less than half 
of the patients achieved clearance while previous 
studies on topical antifungals reported a high rate of 
clearance within 2-4 weeks [3].  
 
Figure 3:  A) Clinical presentation at baseline; B) Clinical 
presentation after 6 weeks of treatment 
 
This can be explained by the direct action of 
topical antifungals on the yeasts in skin lesions. Oral 
itraconazole is absorbed through the gastrointestinal 
tract, metabolised at the liver, and eventually 
distributed to the skin; thus, takes a longer time to 
exert its fungicidal activity. 
Other studies reported clinical response within 
the first month and their effectiveness was maintained 
over 3-14 months [5]. Meanwhile, topical agents are 
also known for their high recurrence rate: patients 
treated with topical antifungals relapsed after 2-4 
weeks [3]. 
Adherence is a problem in the treatment of 
any chronic conditions. Applying topical agents daily 
for months might be challenging for patients. Kruk et 
al., (2006) compared doses intermittently and daily 
and found better adherence when patients took the 
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intermittently dosed [6], [7]. Therefore, the current 
dosing regimen of oral itraconazole can benefit 
patients, especially those who require long-term 
treatment or tend to poorly adhere to therapy. 
We did not record any side effects of oral 
itraconazole, and neither previous studies had 
reported any [5]. This can be a strength of oral 
itraconazole compared with other oral agents since 
adverse effects have been reported in the studies of 
oral terbinafine, fluconazole, and ketoconazole [5]. 
In conclusion, in our study oral itraconazole 
appears to be effective in the treatment of seborrheic 
dermatitis with a good safety profile and good 
adherence in Vietnamese patients. 
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